Abstract
Objectives
To review the methods and developments in maintaining extracorporeal circuits in critically ill patients.
Design
The review includes details of the pathophysiological processes of haemostasis and coagulation in critically ill patients, methods of maintaining blood flow in the extracorporeal circuit and methods of monitoring anticoagulation agents used.
Setting
Information is relevant to the management of critically ill patients requiring extracorporeal renal and respiratory support and cardiopulmonary bypass.
Conclusions
Heparin is the mainstay of anticoagulation for the extracorporeal circuit although the complex abnormalities of the coagulation system in critically ill patients are associated with a considerable risk of bleeding. Alternative therapeutic agents and physical strategies (prostacyclin, low molecular weight heparin, sodium citrate, regional anticoagulation, heparin bonding and attention to circuit design) may reduce the risk of bleeding but expense and difficulty in monitoring are disadvantages.
Similar content being viewed by others
References
Hellgren M, Egberg N, Eklund J (1984) Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients. Intensive Care Med 10:23–28
Colman RW, Walsh PN (1987) Mechanisms of platelet aggregation. In: Colman RW, Hirsh, J, Marder VJ, Salzman EW (eds) Haemostasis and thrombosis. Lippincott, Philadelphia, pp 594–605
Holmsen H (1987) Platelet secretion. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Haemostasis and thrombosis. Lippincott, Philadelphia, pp 606–617
Sixma JJ (1987) Role of blood platelets, plasma proteins and the vessel wall haemostasis. In: Bloom AL, Thomas, DP (eds) Haemostasis and thrombosis. Churchill Livingstone, Edinburgh, pp 283–302
Walsh PN (1982) The effects of collagen and kaolin on the intrinsic coagulant activities of platelets: evidence of an alternative pathway in intrinsic pathway in coagulation not requiring factor XII. Br J Haematol 22:393–405
Zur M, Nemerson Y (1981) Tissue factor pathways of blood coagulation. In: Bloom AL, Thomas DP (eds) Haemostasis and thrombosis, Churchill Livingstone, Edinburgh, pp 124–139
Schmaier AH, Silverberg M, Kaplan AP, Colman RW (1987) Contact activation and its abnormalities. In: Colman RW, Hirsh, J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis. Lippincott, Philadelphia, pp 18–38
Kaplan AP, Meier HL, Mandle RJ (1976) The Hageman factor dependent pathways of coagulation, fibrinolysis, and kinin generation. Semin Thromb Hemost 3:1–26
de Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M (1984) Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-INH. J Clin Invest 73:1542–1549
Harpel PC (1987) Blood proteolytic enzyme inhibitors: their role in modulating blood coagulation and fibrinolytic enzyme pathways. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Haemostasis and thrombosis. Lippincott, Philadelphia, pp 219–234
Owen WG, Esmon CT (1981) Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 256:5532–5535
Rao LV, Rapaport SI, Bajaj SP (1986) Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood 68:685–691
Oohira A, Wight TN, Bornstein P (1983) Sulfated proteoglycans synthesized by vascular endothelial cells in culture. J Biol Chem 258:2014–2021
Marcum JA, Rosenberg RD (1987) Anticoagulantly active heparin sulfate proteoglycan and the vascular endothelium. Semin Thromb Hemost 13:464–474
Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA (1984) Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human endothelial cells. J Exp Med 160:618–623
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran S, Gimbrone MA (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with actions of interleukin 1. Proc Natl Acad Sci USA 83:4533–4537
Hack CE, Nuijens JH, Strack van Schijndel RJM, Abbink JJ, Eerenberg AJM, Thijs LG (1990) A model for the interplay of inflammatory mediators in sepsis — a study in 48 patients. Intensive Care Med 16:S187-S191
Hesselvik JF, Blombäck M, Brodin B, Maller R (1989) Coagulation, fibrinolysis and kallikrein systems in sepsis: relation to outcome. Crit Care Med 17:724–733
Woodman RC, Harker LA (1990) Bleeding complications associated with cardiopulmonary bypass. Blood 76: 1680–1697
Thomson C, Forbes CD, Prentice CR (1973) The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med 45:485–494
Lazarowski ER, Santome JA, Behrens NH, Sanchez Avalos JC (1986) Aggregation of human neutrophils be heparin. Thromb Res 41:437–446
Saba HI, Saba SR, Blackburn CA, Hartmann RC, Mason RG (1979) Heparin neutralization of PGI2: effects upon platelets. Science 205:499–501
Davies GC, Sobel M, Salzman EW (1980) Elevated plasma fibrinopeptide A and thromboxane A2 levels during cardiopulmonary bypass. Circulation 61:808–814
George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ (1986) Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 78:340–348
Dechavanne M, Ffrench M, Pages J, Ffrench P, Boukerche H, Bryon PA, McGregor JL (1987) Significant reduction in the binding of a monoclonal antibody (LYP 18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation. Thromb Haemost 57:106–109
Wenger RK, Lukasiewicz H, Mikuta BS, Niewiarowski S, Edmunds LHJ (1989) Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 97:235–239
Abrams CS, Ellison N, Budzynski AZ, Shattil SJ (1990) Difect detection of activated platelets and platelet-derived microparticles in humans. Blood 75:128–138
Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, Wenger RK, Rucinski B, Niewiarowski S, Edmunds LHJ (1987) Human neutrophil degranulation during extracorporeal circulation. Blood 69: 324–330
Wachtfogel YT, Harpel PC, Edmunds LHJ, Colman RW (1989) Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-α2-plasmin inhibitor complexes during cardiopulmonary bypass. Blood 73:468–471
Gallimore MJ, Heller W, Fuhrer G, Wendel H, Klaffschenkel R, Hoffmeister HE (1992) Contact activation, heparins and cardiopulmonary bypass. Thromb Haemost 68:91–92
Furie B, Furie BC (1992) Molecular and cellular biology of blood coagulation. N Engl J Med 326:800–806
McLean J (1916) The thromboplastic action of cephalin. Am J Physiol 41:250
Gregorius FK, Rand RW (1976) Scanning electron microscopy of the rat common carotid artery. III. Heparin effects on platelets. Surgery 79:583–589
Chen J, Karlberg K-E, Sylven C (1991) Heparin and low molecular weight heparin but not hirudin stimulate platelet aggregation in whole blood from acetylsalicylic acid treated healthy volunteers. Thromb Res 63:319–329
Zucker MB (1975) Effect of heparin on platelet function. Thromb Diath Haemorrh 33:63–65
Michalski R, Lane DA, Kakkar VJ (1977) Comparison of heparin and a semisynthetic heparin analogue. II. Some effects on platelet function. Br J Haematol 37:247–256
Bestermann EM, Gillet MP (1973) Heparin effects on plasma lysolecithin formation and platelet aggregation. Atherosclerosis 17:503–513
Koch KM, Bechstein PB, Fassbinder W, Kaltwasser P, Schoeppe W (1975) Occult blood loss and iron balance in chronic renal failure. Proc EDTA 112: 681–684
Chong BH, Berndt MC (1989) Heparin induced thrombocytopenia. Blut 58: 53–57
Gallimore MJ, Fuhrer G, Heller W, Hoffmeister HE (1991) The effects of fractionated and unfractionated heparins with and without aprotinin on plasma inhibition of alpha and beta FXII a. Agents&Actions 38:257–264
Bjornsson TD, Wolfram KM, Kitchell BB (1982) Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 31:104–113
Schapira M, Christman BW (1990) Neutralization of heparin and protamine. Time for a change? Circulation 82:1877–1879
Kaplan AA, Petrillo R (1987) Regional heparinization for continuous arteriovenous hemofiltration (CAVH). Asaio Trans 33:312–315
Teng CL, Kim JS, Port FK, Wakefield TW, Till GO, Yang VC (1988) A protamine filter for extracorporeal blood heparin removal. Asaio Trans 34:743–746
Larm O, Larsson R, Olsson P (1983) A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomat Med Dev Artif Org 2:161–173
Arnander C, Dryjski M, Larsson R, Olsson P, Swedenborg J (1986) Thrombin uptake and inhibition on endothelium and surfaces with a stable heparin coating. A comparative in vitro study. J Biomed Mater Res 20:235–246
Bindslev L, Eklund J, Norlander O, Swedenborg J, Olsson P, Nilsson E, Larm O, Gouda I, Malmberg A, Scholander E (1987) Treatment of acute respiratory failure by extracorporeal carbon dioxide elimination performed with a surface heparinized artificial lung. Anesthesiology 67:117–120
Peters J, Radermacher P, Kuntz ME, Rosenbauer KA, Breulmann M, Bürrig KF, Hopf HB, Rossaint R, Schulte HD, Olsson P, Falke KJ (1988) Extracorporeal CO2 removal with a heparin coated artificial lung. Intensive Care Med 14:578–584
Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H, Seidel D, Scheler F (1988) Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 33:890–896
Schrader J, Stibbe W, Kandt M, Warneke G, Armstrong V, Muller HJ, Scheler F (1990) Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients. ASAIO Trans 36:28–32
Bertele V, Roncanglione MC, Donati MB, de Gaetano G (1983) Heparin counteracts the antiaggregating effect of prostacyclin by potentiating platelet aggregation. Thromb Haemost 49: 81–83
Turney JH, Williams LC, Fewell MR, Parsons V, Weston MJ (1980) Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet II:224–226
Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N (1981) Haemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 304:934–939
Keogh A, Rylance P, Weston M, Parsons V (1984) Prostacyclin haemodialysis in patients at risk of haemorrhage. Proc Eur Dial Trans Assoc 13:51–54
Mehta RL, McDonald BR, Aguilar MM, Ward DM (1990) Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 38:976–981
Ahmad S, Yeo KT, Jensen WM, Landicho D, Geogory B, Moritz JL, Kenny M (1990) Citrate anticoagulation during in vivo simulation of slow hemofiltration. Blood Purif 8:177–182
Chien S, Jan KM (1973) Ultrastructural basis of the mechanism of rouleaux formation. Microvasc Res 5:155–166
Webb AR, Nash GB, Dormandy JA, Bennett ED (1990) A comparison of the effects of artificial plasma substitutes, albumin and saline solutions on in vitro apparent blood viscosity. Clin Hemorheol 10:287–296
Wendon J, Smithies M, Sheppard M, Bullen K, Tinker J, Bihari D (1989) Continuous high volume venous-venous haemofiltration in acute renal failure. Intensive Care Med 15:358–363
David S, Cambi V (1992) Hemofiltration: predilution versus postdilution. Contrib Nephrol 96:77–85
Oedekoven B, Bey R, Mottaghy K, Schmid-Schonbein H (1984) Gabexate mesilate (FOY) as an anticoagulant in extracorporeal circulation in dogs and sheep. Thromb Haemost 52:329–332
Royston D (1990) The serine antiprotease aprotinin (Trasylol): a novel approach to reducing postoperative bleeding. Blood Coag Fibrinolysis 1:55–59
Fritz H, Wunderer G (1983) Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 33:479–494
Philipp E (1978) Calculations and hypothetical considerations on the inhibition of plasmin and plasma kallikrein by Trasylol. In: Davidson JF, Rowan RM, Samama MM, Desnoyers PC (eds) Progress in chemical fibrinolysis and thrombolysis. Raven Press, New York, pp 291–295
Fritz H (1978) Inhibition of plasmin and plasma kallikrein by the basic trypsin-kallikrein inhibitor from bovine organs (Trasylol) and similar protease inhibitors — theoretical considerations. In: Davidson JJ, Rowan RM, Samama MM, Desnoyers PC (eds) Progress in chemical fibrinolysis and thrombolysis. Raven Press, New York, pp 285–290
Glenn TM, Herlich BL, Lefer AM (1973) Protective action of a protease inhibitor in hemorrhagic shock. Arch Int Pharmacodyn Ther 203:292–304
Nimmo GR, Cumming AD (1991) The effects of aprotinin in septic shock unresponsive to volume loading. Crit Care Med 19:S16
van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur C (1990) Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Cardiovasc Surg 99:788–797
Del Maschio A, Evangelista V, Rajtar G, Chen Z, Cerletti C, de Gaetano G (1990) Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol 258:H870-H879
Evangelista V, Rajtar G, de Gaetano G, White JG, Cerletti C (1991) Platelet activation by FMLP stimulated polymorphonuclear leukocytes: the activity of Cathepsin G is not prevented by antiproteinases. Blood 77:2379–2388
Faint RW, Mythen MG, Mackie IJ, Machin SJ (1993) Aprotinin inhibits platelet aggregation induced by purified neutrophils. Br J Haematol (in press)
Royston D, Bidstrup BP, Taylor KM, Sapsford RN (1987) Effect of aprotinin on need for blood transfusions after repeat open heart surgery. Lancet II:1289–1291
Dietrich W, Barankay A, Dilthey G, Henze R, Niekau E, Sebening F, Richter JA (1989) Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application. Thorac Cardiovasc Surg 37:92–98
Brunet F, Mira JP, Belghith M, Lanore JJ, Schlumberger S, Toulon P, Dhainaut JF (1992) Effect of aprotinin on hemorhagic complications in ARDS patients during prolonged extracorporeal CO2 removal. Intensive Care Med 18:364–367
Colvin BT, Barrowcliffe TW (1993) The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: Second Revision. Clin Pathol 46:97–103
Francis JL, Howard C (1993) The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin. Blood Coag Fibrinolysis 4:35–40
Wendel HP, Heller W, Gallimore MJ, Bantel H, Muller-Beissenhirtz H, Hoffmeister HE (1993) The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coag Fibrinolysis 4:41–45
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Webb, A.R., Mythen, M.G., Jacobson, D. et al. Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Intensive Care Med 21, 84–93 (1995). https://doi.org/10.1007/BF02425162
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02425162